A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-α down-regulation in breast cancer cells: The role of nuclear factor-κB

Molecular Endocrinology

Volumn 18, Issue 6, 2004, Pages 1396-1410

  Holloway, Jamie N ^a   Murthy, Shalini ^b   El Ashry, Dorraya ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

90KDA RIBOSOMAL S6 KINASE; ESTROGEN RECEPTOR ALPHA; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER MODEL; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASM; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; GENETIC VECTORS; GROWTH SUBSTANCES; HUMANS; LIGANDS; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PLASMIDS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; UP-REGULATION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 2542454563     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0048     Document Type: Article

References (68)

1. McGuire WL, Osborne CK, Clark GM, Knight WA 1982 Steroid hormone receptors and carcinoma of the breast. Am J Physiol 243:E99-E102
2. Knight WA, Livingston RB, Gregory EJ, McGuire WL 1977 Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671
3. Rich M, Furmanski P, Brooks S 1978 Prognostic value of estrogen receptor determinations in patients with breast cancer. Cancer Res 38:4296-4298
4. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331-3338
5. Newby JC, Johnston SR, Smith IE, Dowsett M 1997 Expression of epidermal growth factor receptor and c-erB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3:1643-1651
6. Anderson E, Clarke RB, Howell A 1998 Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 3:23-35
7. Petersen OW, Hoyer PE, Van Deurs B 1987 Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 47:5748-5751
8. Clarke RB, Howell A, Potten CS, Anderson E 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987-4991
9. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP 1999 Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811-1815
10. Ballare C, Bravo AI, Laucella S, Sorin I, Cerdeiro R, Loza J, Sousa MF, Guman N, Mordoh J 1989 DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells. Cancer 64:842-848
11. Russo J, Ao X, Grill C, Russo IH 1999 Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53:217-227
12. Gee JM, Robertson JF, Ellis IO, Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254
13. Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, Wright C, Henry J, Farndon JR, Harris AL 1991 Epidermal growth factor receptor (EGFR); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150
14. Toi M, Hamada Y, Nakamura T, Mukaida H, Suehiro S, Wada T, Toge T, Niimoto M, Hattori T 1989 Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion. Int J Cancer 43:220-225
15. Hainsworth PJ, Henderson MA, Stillwell RG, Bennett RC 1991 Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur J Surg Oncol 17:9-15
16. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, Blamey RW, Ellis IO 1990 Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43:385-389
17. Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T 1990 Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65:1980-1984
18. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ 2000 Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 62:167-175
19. Hermanto U, Zong CS, Wang LH 2000 Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Cell Growth Differ 11:655-664
20. Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B, Linder S 1999 ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 17:649-654
21. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE 1996 Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7:351-359
22. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC 1999 Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5:251-256
23. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ 1999 cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18:6063-6070
24. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW 1997 Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
25. Liu ZG, Hsu H, Goeddel DV, Karin M 1996 Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565-576
26. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R 1993 Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 90:9901-9905
27. Wang CY, Mayo MW, Baldwin Jr AS 1996 TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274:784-787
28. Siebenlist U, Franzoso G, Brown K 1994 Structure, regulation and function of NF-κB. Annu Rev Cell Biol 10:405-455
29. Norris JL, Baldwin Jr AS 1999 Oncogenic Ras enhances NF-κB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J Biol Chem 274:13841-13846
30. Pearson G, English JM, White MA, Cobb MH 2001 ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation. J Biol Chem 276:7927-7931
31. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE 1994 The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95
32. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG 1994 Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5:1263-1274
33. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG 1995 MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117
34. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
35. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC 1999 Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 53:229-240
36. Frodin M, Gammeltoft S 1999 Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151:65-77
37. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18:1978-1984
38. Chuang CF, Ng SY 1994 Functional divergence of the MAP kinase pathway. ERK1 and ERK2 activate specific transcription factors. FEBS Lett 346:229-234
39. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG 1996 Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423-435
40. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG 1994 Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-970
41. Kortenjann M, Shaw PE 1995 Raf-1 kinase and ERK2 uncoupled from mitogenic signals in rat fibroblasts. Oncogene 11:2105-2112
42. Robinson MJ, Harkins PC, Zhang J, Baer R, Haycock JW, Cobb MH, Goldsmith EJ 1996 Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5′-triphosphate. Biochemistry 35:5641-5646
43. Gee JM, Ellis IO, Robertson JF, Willsher P, McClelland RA, Hewitt KN, Blamey RW, Nicholson RI 1995 Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 64:269-273
44. Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K 1999 Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 84:533-538
45. Treinies I, Paterson HF, Hooper S, Wilson R, Marshall CJ 1999 Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal to stimulate DNA synthesis. Mol Cell Biol 19:321-329
46. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI 2000 Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89:177-186
47. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH 2001 AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20:2771-2780
48. Roux PP, Richards SA, Blenis J 2003 Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23:4796-4804
49. Pearson G, Robinson F, Beers GT, Xu BE, Karandikar M, Berman K, Cobb MH 2001 Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183
50. Eblen ST, Catling AD, Assanah MC, Weber MJ 2001 Biochemical and biological functions of the N-terminal, noncatalytic domain of extracellular signal-regulated kinase 2. Mol Cell Biol 21:249-259
51. McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M 1995 Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev 9:1953-1964
52. Troppmair J, Hartkamp J, Rapp UR 1998 Activation of NF-κB y oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade. Oncogene 17:685-690
53. Koo TH, Lee JH, Park YJ, Hong YS, Kim HS, Kim KW, Lee JJ 2001 A sesquiterpene lactone, costunolide, from Magnolia grandiflora inhibits NF-κB by targeting I κB Phosphorylation. Planta Med 67:103-107
54. Toi M, Osaki A, Yamada H, Toge T 1991 Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980
55. Wright C, Nicholson S, Angus B, Sainsbury J, Farndon JR, Cairns J, Harris AL, Horne CHW 1992 Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121
56. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC 1997 Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99:1478-1483
57. Sharma AK, Morgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R 1994 Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69:1032-1037
58. Murakami M, Ui MIH 1999 Fra-2-positive autoregulatory loop triggered by mitogen-activated-protein kinase (MAPK) and Fra-2 phosphorylation sites by MAPK. Cell Growth Differ 10:333-342
59. Tang Z, Treilleux I, Brown M 1997 A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers. Mol Cell Biol 17:1274-1280
60. Doucas V, Spyrou G, Yaniv M 1991 Unregulated expression of c-Jun or c-Fos proteins but not Jun D inhibits oestrogen receptor activity in human breast cancer derived cells. EMBO J 10:2237-2245
61. Tzukerman M, Zhang XK, Pfahl M 1991 Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradeconylphorbol-13-acetate: a molecular analysis. Mol Endocrinol 5:1983-1992
62. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
63. Smith CL 1998 Cross-talk between peptide growth factor and estrogen receptor signaling. Biol Reprod 58:627-632
64. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa J-PJ, Davidson NE 1996 Methylation of estrogen and progesterone receptor genes 5′ CpG islands correlates with ER and PR gene expression in breast tumors. Clin Cancer Res 2:805-810
65. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin Jr AS 1997 Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812-1815
66. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet Jr RJ, Sledge Jr GW, Nakshatri H 2000 Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19:4159-4169
67. El-Ashry D, Lippman ME, Kern FG, Human transforming growth factor-α contains an estrogen responsive element comprised of two imperfect palindromes. Proc 73rd Annual Meeting of The Endocrine Society, Washington, DC, 1991, p 268 (Abstract 950)
68. Edwards DP, McGuire WL 1980 17α-Estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. Endocrinology 107:884-891